共 26 条
[1]
Overcoming restenosis with sirolimus:Fromalphabet soupto clinical reality. Poon M,Badimon JJ,Fuster V. The Lancet . 2002
[2]
Drug-elutingstents:Newera and new concerns. Bhatia V,Bhatia R,Dhindsa M. Postgraduate Medical Journal . 2004
[3]
Drugelutingstents:Are human and animal studies comparable. Virmani P,Kolodgie FD,Farb A,et al. Heart . 2003
[4]
Stent-based delivery of sirolimuse reduces neointimal formation andin-stent restenosisin a porcine coronary model. Suzuki K,Kopia G,Bailey L,et al. Circulation . 2001
[5]
Drug-eluting stents in vascular intervention. Fattori R and Piva T. The Lancet . 2003
[6]
Unrestricted Utilization of Sirolimus-Eluting Stents Compared with Conventional Bare Stent Im-plantationinthe"Real World".The Rapamycin-Eluting Stent Evaluated at RotterdamCardiology Hospital(RESEARCH)Registry. Lemos PA,Serruys PW,van Domburg RT,et al. Circulation . 2004
[7]
Heart[P]. 英国专利:GB0418877D0,2004-09-29
[8]
Quantitative assessment of angio-graphic restenosis after sirolimus-elutingstentimplantationin native coro-nary arteries. Popma JJ,Leon MB,Moses JW,et al. Circulation . 2004
[9]
Prevention of lesionrecurrence in chronic total coronary occlusions by paclitaxel-eluting stents. Werner GS,Krack A,Schwarz G,et al. Journal of the American College of Cardiology . 2004
[10]
Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries:Aquantitative coronary angiography and three-dimensional intravascular ultrasound study. Sousa JE,Costa MA,Abizaid A,et al. Circulation . 2001